Investigation of Serum PIVKA-II Levels in Patients with Helicobacter pylori Infection and Normal Group

Document Type : Research/Original Article

Authors

1 Gasteroenterohepatology Research Center Shiraz University of Medical Sciences Shiraz, Iran

2 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, IranShiraz

3 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Fars, Shiraz, Iran

4 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

5 Institute for Cancer Research, Shiraz University of Medical Science, Shiraz, Iran

Abstract

Abstract
Background: Helicobacter pylori is one of the most common microorganisms known in humans, and as a risk factor it can result in gastric cancer, therefore we decided to evaluate the serum level of PIVKA-II in patients with Helicobacter pylori (H. pylori) infection and normal group.
Materials and Methods: This study was performed on 90 patients (45 patients with H. pylori infection and 45 patients in the control group). After recording demographic information, serum level of PIVKA-II was measured in two groups by ELISA method.
Results: The findings of our study showed no significant difference between the serum level of PIVKA-II in patients with H. pylori compared to those without infection (p = 0.08) but at the age of less than 40 years, the mean serum level of PIVKA-II in patients with H. pylori was significantly lower than the control group (p = 0.026), Also in men infected by H. pylori the mean serum level of PIVKA-II was significantly less than the control group. (p = 0.04)
Conclusion: The results of the present study indicate that the serum level of PIVKA-II in infected men as well as in people under 40 years of age with H. pylori infection, was significantly lower than the control group. Also, serum PIVKA-II levels in patients were significantly lower in men than women and in those under 40 years of age compared with those over 40 years of age.

Keywords

References

  1.  

    1. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. The Lancet. 2008;372(9636):392-7.
    2. Holleczek B, Schöttker B, Brenner H. Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: results from the prospective population‐based ESTHER cohort study. International journal of cancer. 2020;146(10):2773-83.
    3. Wu M-S, Chen C-J, Lin J-T. Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiology Biomarkers & Prevention. 2005;14(8):1878-82.
    4. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European journal of cancer. 2018;103:356-87.
    5. Tartaglione S, Pecorella I, Zarrillo SR, Granato T, Viggiani V, Manganaro L, et al. Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study. Biochemia Medica. 2019;29(2):352-8.
    6. Furie B, Furie BC. Molecular basis of vitamin K-dependent γ-carboxylation. Blood. 1990;75(9):1753-62.
    7. Kim J-H, Jun K-H, Jung H, Park I-S, Chin H-M. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer. Hepato-gastroenterology. 2014;61(131):863-9.
    8. Yang A-P, Liu J, Lei H-Y, Zhang Q-W, Zhao L, Yang G-H. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer. Clinica chimica acta. 2014;437:183-6.
    9. Ishii T, Ozasa R, Miyajima N, Bann N, Hirata Y, Ishidate T, et al. A case of AFP and PIVKA-II producing gastric carcinoma forming a massive tumor embolus in the portal vein. Nihon Shokakibyo Gakkai Zasshi= The Japanese Journal of Gastro-enterology. 2002;99(3):275-81.
    10. Tanaka H, Ishii S, Akutsu N, Ohashi H, Tokuno T, Suzuki T, et al. A case of AFP and PIVKA-II producing gastric carcinoma. Nihon Shokakibyo Gakkai Zasshi= The Japanese Journal of Gastro-enterology. 2006;103(4):426-31.
    11. Takano S, Honda I, Watanabe S, Soda H, Nagata M, Hoshino I, et al. PIVKA-II-producing advanced gastric cancer. International Journal of Clinical Oncology. 2004;9:330-3.
    12. Okuse C, Yotsuyanagi H, Takahashi Y, Hayashi T, Suzuki M, Iino S, et al. Gastric cancer with liver metastasis producing alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II); a case report. Nihon Shokakibyo Gakkai Zasshi= The Japanese Journal of Gastro-enterology. 2003;100(1):28-34.
    13. Takahashi Y, Inoue T, Fukusato T. Protein induced by vitamin K absence or antagonist II-producing gastric cancer. World Journal of Gastrointestinal Pathophysiology. 2010;1(4):129.
    14. Iso Y, Sawada T, Shimoda M, Rokkaku K, Ohkura Y, Kubota K. Solitary AFP-and PIVKA-II-producing hepatoid gastric cancer with giant lymph node metastasis. Hepato-gastroenterology. 2005;52(66):1930-2.
    15. Kucera R, Smid D, Topolcan O, Karlikova M, Fiala O, Slouka D, et al. Searching for new biomarkers and the use of multivariate analysis in gastric cancer diagnostics. Anticancer Research. 2016;36(4):1967-71.
    16. Kim YJ, Lim TS, Kim JD, Jeon WJ, Kim H, Park HW, et al. PS 1060; Gastroenterology (Gastrointestinal Tract); Gastric Hepatoid Adenocarcinoma with Increased Serum Levels of Alpha-Fetoprotein and Prothrombin Induced by Vitamin K Absence Ii in Patient with Chronic Liver Disease. 2014;2014(1):255-.
    17. Takahashi Y, Inoue T. Des‐γ carboxy prothrombin (PIVKA‐II) and α‐fetoprotein producing gastric cancer with multiple liver metastases. Pathology international. 2003;53(4):236-40.

Files

Share

How to cite

Statistics